Creo Medical Group (LON:CREO) Insider Richard John Rees Acquires 6,250 Shares

Creo Medical Group PLC (LON:CREO) insider Richard John Rees acquired 6,250 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was purchased at an average cost of GBX 14 per share, with a total value of £875.

Creo Medical Group Stock Down 2.5%

Shares of LON CREO opened at GBX 14.38 on Tuesday. The firm’s 50 day moving average price is GBX 13.22 and its 200 day moving average price is GBX 12.93. The company has a debt-to-equity ratio of 8.20, a quick ratio of 2.19 and a current ratio of 3.22. The firm has a market cap of £69.83 million, a P/E ratio of 14.38 and a beta of 1.62. Creo Medical Group PLC has a 1 year low of GBX 9.52 and a 1 year high of GBX 18.50.

Creo Medical Group (LON:CREO) last posted its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share (EPS) for the quarter. The business had revenue of GBX 600 million for the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. As a group, sell-side analysts anticipate that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Shore Capital Group restated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a report on Monday, June 29th.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.